Adrenoleukodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major adrenoleukodystrophy markets reached a value of US$ 239.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 290.2 Million by 2034, exhibiting a growth rate (CAGR) of 1.77% during 2024-2034.
The adrenoleukodystrophy market has been comprehensively analyzed in IMARC's new report titled "Adrenoleukodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Adrenoleukodystrophy (ALD) is a rare and hereditary disorder that affects the adrenal glands and nervous system. It falls under the category of leukodystrophies, a group of genetic disorders impacting the myelin sheath, the protective layer of nerve fibers in the brain. The symptoms of ALD can manifest in various ways, depending on the type and severity of the disease. Common initial signs include behavioral changes, difficulty concentrating, and deteriorating school performance. As the disease progresses, individuals suffering from the disorder may experience muscle weakness, visual disturbances, impaired coordination, and even severe cognitive and motor problems. In some cases, ALD can also lead to adrenal insufficiency, resulting in hormonal imbalances. Diagnosing the ailment often involves a combination of clinical evaluation, neuroimaging studies, such as MRI, and specialized biochemical tests to assess the levels of certain fatty acids in the blood. Physicians might also perform genetic testing to confirm the presence of mutations associated with ALD.
The escalating cases of genetic variations within the ABCD1 gene, culminating in the disruption of peroxisomal functions and the subsequent accumulation of very long-chain fatty acids (VLCFA), are primarily driving the adrenoleukodystrophy market. In addition to this, the inflating utilization of combination treatments, including glyceryl trioleate and glyceryl trierucate, which aim to reduce the buildup of VLCFAs and mitigate neurological damage in patients, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive care strategies, such as physical and occupational therapies tailored to address mobility challenges and enhance daily functioning, is further bolstering the market growth. These therapies aid in fortifying muscle strength, refining coordination, and augmenting gross motor skills, thus increasing the overall standard of living for individuals suffering from ALD. Additionally, the rising usage of potent medications, like corticosteroids, to manage adrenal gland dysfunctions and alleviate the progression of the disease is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of gene therapy for the treatment of the illness by introducing functional genetic material to rectify or replace the defective ABCD1 gene responsible for the disorder is expected to drive the adrenoleukodystrophy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the adrenoleukodystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for adrenoleukodystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adrenoleukodystrophy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the adrenoleukodystrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the adrenoleukodystrophy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current adrenoleukodystrophy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the adrenoleukodystrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the adrenoleukodystrophy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the adrenoleukodystrophy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of adrenoleukodystrophy across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of adrenoleukodystrophy by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of adrenoleukodystrophy by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with adrenoleukodystrophy across the seven major markets?
What is the size of the adrenoleukodystrophy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of adrenoleukodystrophy?
What will be the growth rate of patients across the seven major markets?
Adrenoleukodystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for adrenoleukodystrophy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adrenoleukodystrophy market?
What are the key regulatory events related to the adrenoleukodystrophy market?
What is the structure of clinical trial landscape by status related to the adrenoleukodystrophy market?
What is the structure of clinical trial landscape by phase related to the adrenoleukodystrophy market?
What is the structure of clinical trial landscape by route of administration related to the adrenoleukodystrophy market?
The adrenoleukodystrophy market has been comprehensively analyzed in IMARC's new report titled "Adrenoleukodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Adrenoleukodystrophy (ALD) is a rare and hereditary disorder that affects the adrenal glands and nervous system. It falls under the category of leukodystrophies, a group of genetic disorders impacting the myelin sheath, the protective layer of nerve fibers in the brain. The symptoms of ALD can manifest in various ways, depending on the type and severity of the disease. Common initial signs include behavioral changes, difficulty concentrating, and deteriorating school performance. As the disease progresses, individuals suffering from the disorder may experience muscle weakness, visual disturbances, impaired coordination, and even severe cognitive and motor problems. In some cases, ALD can also lead to adrenal insufficiency, resulting in hormonal imbalances. Diagnosing the ailment often involves a combination of clinical evaluation, neuroimaging studies, such as MRI, and specialized biochemical tests to assess the levels of certain fatty acids in the blood. Physicians might also perform genetic testing to confirm the presence of mutations associated with ALD.
The escalating cases of genetic variations within the ABCD1 gene, culminating in the disruption of peroxisomal functions and the subsequent accumulation of very long-chain fatty acids (VLCFA), are primarily driving the adrenoleukodystrophy market. In addition to this, the inflating utilization of combination treatments, including glyceryl trioleate and glyceryl trierucate, which aim to reduce the buildup of VLCFAs and mitigate neurological damage in patients, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive care strategies, such as physical and occupational therapies tailored to address mobility challenges and enhance daily functioning, is further bolstering the market growth. These therapies aid in fortifying muscle strength, refining coordination, and augmenting gross motor skills, thus increasing the overall standard of living for individuals suffering from ALD. Additionally, the rising usage of potent medications, like corticosteroids, to manage adrenal gland dysfunctions and alleviate the progression of the disease is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of gene therapy for the treatment of the illness by introducing functional genetic material to rectify or replace the defective ABCD1 gene responsible for the disorder is expected to drive the adrenoleukodystrophy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the adrenoleukodystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for adrenoleukodystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adrenoleukodystrophy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the adrenoleukodystrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the adrenoleukodystrophy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current adrenoleukodystrophy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the adrenoleukodystrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the adrenoleukodystrophy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the adrenoleukodystrophy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of adrenoleukodystrophy across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of adrenoleukodystrophy by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of adrenoleukodystrophy by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with adrenoleukodystrophy across the seven major markets?
What is the size of the adrenoleukodystrophy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of adrenoleukodystrophy?
What will be the growth rate of patients across the seven major markets?
Adrenoleukodystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for adrenoleukodystrophy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adrenoleukodystrophy market?
What are the key regulatory events related to the adrenoleukodystrophy market?
What is the structure of clinical trial landscape by status related to the adrenoleukodystrophy market?
What is the structure of clinical trial landscape by phase related to the adrenoleukodystrophy market?
What is the structure of clinical trial landscape by route of administration related to the adrenoleukodystrophy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ADRENOLEUKODYSTROPHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ADRENOLEUKODYSTROPHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ADRENOLEUKODYSTROPHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ADRENOLEUKODYSTROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ADRENOLEUKODYSTROPHY - UNMET NEEDS
10 ADRENOLEUKODYSTROPHY - KEY ENDPOINTS OF TREATMENT
11 ADRENOLEUKODYSTROPHY - MARKETED PRODUCTS
11.1 List of Adrenoleukodystrophy Marketed Drugs Across the Top 7 Markets
11.1.1 Skysona (Elivaldogene Autotemcel) - Bluebird bio
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ADRENOLEUKODYSTROPHY - PIPELINE DRUGS
12.1 List of Adrenoleukodystrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 Leriglitazone - Minoryx Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PXL065 - Poxel
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VK0214 - Viking Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ADRENOLEUKODYSTROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ADRENOLEUKODYSTROPHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ADRENOLEUKODYSTROPHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Adrenoleukodystrophy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Adrenoleukodystrophy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Adrenoleukodystrophy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Adrenoleukodystrophy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Adrenoleukodystrophy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Adrenoleukodystrophy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Adrenoleukodystrophy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Adrenoleukodystrophy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Adrenoleukodystrophy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Adrenoleukodystrophy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Adrenoleukodystrophy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Adrenoleukodystrophy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Adrenoleukodystrophy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Adrenoleukodystrophy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Adrenoleukodystrophy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Adrenoleukodystrophy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Adrenoleukodystrophy - Access and Reimbursement Overview
16 ADRENOLEUKODYSTROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ADRENOLEUKODYSTROPHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ADRENOLEUKODYSTROPHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ADRENOLEUKODYSTROPHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ADRENOLEUKODYSTROPHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ADRENOLEUKODYSTROPHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ADRENOLEUKODYSTROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ADRENOLEUKODYSTROPHY - UNMET NEEDS
10 ADRENOLEUKODYSTROPHY - KEY ENDPOINTS OF TREATMENT
11 ADRENOLEUKODYSTROPHY - MARKETED PRODUCTS
11.1 List of Adrenoleukodystrophy Marketed Drugs Across the Top 7 Markets
11.1.1 Skysona (Elivaldogene Autotemcel) - Bluebird bio
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ADRENOLEUKODYSTROPHY - PIPELINE DRUGS
12.1 List of Adrenoleukodystrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 Leriglitazone - Minoryx Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PXL065 - Poxel
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VK0214 - Viking Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ADRENOLEUKODYSTROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ADRENOLEUKODYSTROPHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ADRENOLEUKODYSTROPHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Adrenoleukodystrophy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Adrenoleukodystrophy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Adrenoleukodystrophy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Adrenoleukodystrophy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Adrenoleukodystrophy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Adrenoleukodystrophy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Adrenoleukodystrophy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Adrenoleukodystrophy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Adrenoleukodystrophy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Adrenoleukodystrophy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Adrenoleukodystrophy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Adrenoleukodystrophy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Adrenoleukodystrophy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Adrenoleukodystrophy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Adrenoleukodystrophy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Adrenoleukodystrophy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Adrenoleukodystrophy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Adrenoleukodystrophy - Access and Reimbursement Overview
16 ADRENOLEUKODYSTROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ADRENOLEUKODYSTROPHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ADRENOLEUKODYSTROPHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
